Literature DB >> 26550286

Association between IL-6 and related risk factors of metabolic syndrome and cardiovascular disease in young rats.

Pengli Bao1, Geli Liu1, Ying Wei1.   

Abstract

OBJECTIVE: Metabolic syndrome (MS) is conceived as the pathogenic basis of an increased cardiovascular burden. We investigate the correlation between interleukin-6 (IL-6) and the risk factors of MS and cardiovascular disease (CVD) in diet-induced model of MS and determined whether IL-6 was associated with the prevalence of MS and cardiovascular disease.
METHODS: A total of 40 Spague-Dawley (SD) rats were randomly divided into high-fat and high salt (FSC) group, high-fat (FC) group and normal control (NC) group. After feeding for 7 weeks, fasting blood glucose (FBG) and fasting insulin (FIN) were measured at the 60 min, 120 min and 180 min after the glucose administration. Blood pressure, body weight, height, waist circumference (WC), liver weight, visceral fat weight as well as blood lipid profile were determined at the end of 7-week. Furthermore, IL-6 levels from adipose tissues were analyzed using ELISA, and the correlation between IL-6 and the risk factors of MS and cardiovascular disease was investigated.
RESULTS: After treatment with different diets, significant difference was noted in the WC, body mass index (BMI), visceral fat weight and liver weight of FSC group compared with those of NC group (P<0.05). The levels of systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), triacylglycerol (TG) and low density lipoprotein (LDL) were markedly elevated in FSC group compared with those in NC group, while the level of high density lipoprotein (HDL) was remarkable lower in FSC group (P<0.05). After glucose administration, the concentrations of blood glucose and insulin were significant higher in FSC group than those in NC group at different time points (P<0.05). Moreover, high-fat and high salt diet brought about significant elevation of IL-6 compared with that with normal or high-fat diet in SD rats. Furthermore, IL-6 was significantly associated with FIN, HOMA-IR, LDL, TC, TG, HDL, visceral fat mass and body weight in FSC group, while IL-6 was markedly correlated with TC, LDL, TG, visceral fat mass and body weight (P<0.05).
CONCLUSION: A characteristic rat model of MS may be induced by the high-fat and high-salt diet. IL-6 may be considered as an early and representative marker in the pathogenesis of MS and related cardiovascular burden.

Entities:  

Keywords:  IL-6; animal model; cardiovascular disease; metabolic syndrome; obesity

Year:  2015        PMID: 26550286      PMCID: PMC4612971     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  41 in total

1.  Innate immunity, insulin resistance and type 2 diabetes.

Authors:  J M Fernández-Real; J C Pickup
Journal:  Diabetologia       Date:  2011-11-30       Impact factor: 10.122

Review 2.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

3.  Raised interleukin-6 levels in obese patients.

Authors:  L Roytblat; M Rachinsky; A Fisher; L Greemberg; Y Shapira; A Douvdevani; S Gelman
Journal:  Obes Res       Date:  2000-12

4.  Obesity and IL-6 interact in modulating the response to endotoxemia in mice.

Authors:  Maria Pini; Karla J Castellanos; Davina H Rhodes; Giamila Fantuzzi
Journal:  Cytokine       Date:  2012-09-23       Impact factor: 3.861

Review 5.  Origin of atherosclerosis in childhood and adolescence.

Authors:  H C McGill; C A McMahan; E E Herderick; G T Malcom; R E Tracy; J P Strong
Journal:  Am J Clin Nutr       Date:  2000-11       Impact factor: 7.045

6.  PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue.

Authors:  Toshiya Matsubara; Ayako Mita; Kohtaro Minami; Tetsuya Hosooka; Sohei Kitazawa; Kenichi Takahashi; Yoshikazu Tamori; Norihide Yokoi; Makoto Watanabe; Ei-Ichi Matsuo; Osamu Nishimura; Susumu Seino
Journal:  Cell Metab       Date:  2012-01-04       Impact factor: 27.287

7.  Inflammatory markers and risk of developing type 2 diabetes in women.

Authors:  Frank B Hu; James B Meigs; Tricia Y Li; Nader Rifai; JoAnn E Manson
Journal:  Diabetes       Date:  2004-03       Impact factor: 9.461

8.  Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial.

Authors:  Russell Scott; Mark Donoghoe; Gerald F Watts; Richard O'Brien; Christopher Pardy; Marja-Riitta Taskinen; Timothy M E Davis; Peter G Colman; Patrick Manning; Gregory Fulcher; Anthony C Keech
Journal:  Cardiovasc Diabetol       Date:  2011-11-21       Impact factor: 9.951

9.  A model of metabolic syndrome and related diseases with intestinal endotoxemia in rats fed a high fat and high sucrose diet.

Authors:  Xin Zhou; Dewu Han; Ruiling Xu; Suhong Li; Huiwen Wu; Chongxiao Qu; Feng Wang; Xiangyu Wang; Yuanchang Zhao
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

10.  Prevalence of metabolic syndrome: association with risk factors and cardiovascular complications in an urban population.

Authors:  Gisela Cipullo Moreira; José Paulo Cipullo; Luiz Alberto Souza Ciorlia; Cláudia Bernardi Cesarino; José Fernando Vilela-Martin
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

View more
  8 in total

1.  IL-6 Response to Psychosocial Stress Predicts 12-month Changes in Cardiometabolic Biomarkers in Perimenopausal Women.

Authors:  Anthony S Zannas; Jennifer L Gordon; Alan L Hinderliter; Susan S Girdler; David R Rubinow
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

Review 2.  Confounders in Identification and Analysis of Inflammatory Biomarkers in Cardiovascular Diseases.

Authors:  Qurrat Ul Ain; Mehak Sarfraz; Gayuk Kalih Prasesti; Triwedya Indra Dewi; Neng Fisheri Kurniati
Journal:  Biomolecules       Date:  2021-10-05

3.  Dietary intervention improves health metrics and life expectancy of the genetically obese Titan mouse.

Authors:  Annika Müller-Eigner; Adrián Sanz-Moreno; Irene de-Diego; Anuroop Venkateswaran Venkatasubramani; Martina Langhammer; Raffaele Gerlini; Birgit Rathkolb; Antonio Aguilar-Pimentel; Tanja Klein-Rodewald; Julia Calzada-Wack; Lore Becker; Sergio Palma-Vera; Benedikt Gille; Ignasi Forne; Axel Imhof; Chen Meng; Christina Ludwig; Franziska Koch; John T Heiker; Angela Kuhla; Vanessa Caton; Julia Brenmoehl; Henry Reyer; Jennifer Schoen; Helmut Fuchs; Valerie Gailus-Durner; Andreas Hoeflich; Martin Hrabe de Angelis; Shahaf Peleg
Journal:  Commun Biol       Date:  2022-05-03

4.  Use of a Highly Antioxidant Diet in the Regulation of Adipose Tissue Secretion in Patients after the BIB Procedure.

Authors:  Edyta Balejko; Jerzy Balejko
Journal:  Foods       Date:  2021-05-17

5.  Diagnostic Power of Circulatory Metabolic Biomarkers as Metabolic Syndrome Risk Predictors in Community-Dwelling Older Adults in Northwest of England (A Feasibility Study).

Authors:  Razieh Hassannejad; Hamsa Sharrouf; Fahimeh Haghighatdoost; Ben Kirk; Farzad Amirabdollahian
Journal:  Nutrients       Date:  2021-06-30       Impact factor: 5.717

6.  Data on IL-6 c.-174 G>C genotype and allele frequencies in patients with coronary heart disease in dependence of cardiovascular outcome.

Authors:  Stefan Reichert; Axel Schlitt; Ann-Christin Benten; Britt Hofmann; Hans-Günter Schaller; Susanne Schulz
Journal:  Data Brief       Date:  2016-07-16

7.  A high salt diet inhibits obesity and delays puberty in the female rat.

Authors:  D Pitynski-Miller; M Ross; M Schmill; R Schambow; T Fuller; F W Flynn; D C Skinner
Journal:  Int J Obes (Lond)       Date:  2017-07-04       Impact factor: 5.095

8.  Immunomodulatory Properties of Adipose-Derived Stem Cells Treated with 5-Azacytydine and Resveratrol on Peripheral Blood Mononuclear Cells and Macrophages in Metabolic Syndrome Animals.

Authors:  Katarzyna Kornicka; Agnieszka Śmieszek; Agnieszka Sławomira Węgrzyn; Michael Röcken; Krzysztof Marycz
Journal:  J Clin Med       Date:  2018-10-24       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.